The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

It is encouraging to see these early results, which demonstrate the potential of our existing Injectable Aesthetics portfolio in addressing the effects of medication-driven weight loss on the skin, ...

This latter finding is particularly noteworthy as unwanted GI impacts are generally the most commonly cited side effects of today's leading glucagon-like peptide-1 / glucose-dependent insulinotropic .

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...

From once-weekly subcutaneously injectable medicines agonizing the glucagon-like peptide 1 receptor (GLP-1R), longer-acting ...

Those in the jab trials, however, kept off between 10 and 25 per cent of their body weight over the same timeframe, depending ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...